DelveInsight's Renal Cell Carcinoma Pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Renal Cell Carcinoma treatment.

The FDA has granted Priority Review to durvalumab for the treatment of resectable, early-stage and locally advanced (Stage II-IVA) gastric and gastroesophageal junction cancers.